Khiron Life Sciences Awarded Best Latin American Cannabis Company at Benzinga Cannabis Capital Conference
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) was awarded the Best Latin American Cannabis Company at Benzinga's 2022 Cannabis Capital Conference in Chicago. This recognition highlights Khiron's achievements in establishing a global path for medical cannabis, focusing on patient access and healthcare provider education. The company reported selling over 100,000 bottles in Latin America since 2020 and has a significant operational footprint with clinics in Colombia and Brazil, boasting a capacity for 400,000 consultations annually.
- Awarded Best Latin American Cannabis Company at Benzinga's 2022 Cannabis Capital Conference.
- Exceeding 100,000 bottles sold in Latin America since 2020.
- Strong operational capacity with 400,000 consultations annually in Colombia.
- None.
TORONTO, Sept. 13, 2022 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical cannabis throughout Europe and Latin America, today announced that received the Best Latin American Cannabis Company award at Benzinga's 2022 Cannabis Capital Conference in Chicago.
"This award recognizes our efforts and achievements as a Latin American Company that radiates throughout our international footprint. Khiron Life Sciences is a first mover in developing a global path for medical cannabis in the region, and we are pursuing this approach worldwide. By providing access to medical cannabis for doctors, pharmacists, insurers, and patients, we have created a true end-to-end solution for the medical cannabis industry", commented Alvaro Torres, CEO and Director of Khiron Life Sciences.
Khiron has developed a proven international access business model with highly profitable medical cannabis sales in Colombia, the United Kingdom, Peru, Brazil, Germany and soon Mexico. The Company has been focused on expanding its first-mover advantage where its health center's physical installed capacity it's around 400,000 consults per year in Colombia and more than 20,000 additional annual consults from the recent launch of Zerenia Clinic in Brazil. By Q2 2022, Khiron had exceeded the milestone of selling its first 100,000 bottles in the Latin American region since beginning sales in 2020, maintaining its high gross margins and pricing structure, with a strong portfolio of THC and CBD medical cannabis products.
Khiron's CEO and Director, Alvaro Torres, will be participating on a panel with industry experts, entitled "International Momentum for Medical Cannabis" taking place on Tuesday, September 13, at 2:55pm CT on the Industry Stage, after announcing the acquisition of Pharmadrug GmbH, an EU-GMP & GDP certified manufacturer and distributor in Germany. Mr. Torres will also be presenting Khiron's corporate presentation on Wednesday, September 14, at 11:50am CT on the Investor Stage.
Khiron is a leading global medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and focus on creating access to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Germany, the United Kingdom, Peru, and Brazil and is positioned to commence sales in Mexico. The Company is led by its co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and board of directors.
Visit Khiron online at https://investors.khiron.ca.
Cautionary Statement Regarding Forward-Looking Information
This press release may contain "forward-looking information" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature constitutes forward-looking information. Forward-looking information contained in this news release may include statements pertaining to the expected synergies and benefits to the Company from the acquisition of the Target as well as statements as to business strategy. Forward-looking information and statements contained in this news release reflect management's current beliefs and is based on information currently available and on assumptions that management believes to be reasonable. These assumptions include, but are not limited to, the expected benefits to be realized by Khiron's business as a result of the acquisition of the Target, and assumptions regarding market opportunities in the jurisdictions in which the Company operates and where it seeks to operate.
Although management believes that its expectations and assumptions to be reasonable, forward-looking information is always subject to known and unknown risks, uncertainties and other factors, many of which are beyond the control of management, that may cause actual results to differ materially from those expressed or implied in such forward-looking information. Such risks and uncertainties include but are not limited to the following: general economic conditions, adverse conditions in capital markets, political uncertainties, counterparty risk, failing to obtain required regulatory requirements and approvals, failure to maintain required permits and licences, business integration risks, as well as those other risk factors discussed in Khiron's most recent annual information form which is available on Khiron's SEDAR profile at www.sedar.com.
As a result of the foregoing and other risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking information contained in this press release. Readers are further cautioned that the foregoing risks and uncertainties is not exhaustive, and there may be other risks and uncertainties, presently unknown to management of the Company, that may cause actual results to differ materially from those expressed or implied in forward-looking statements contained in this press release. The forward-looking information contained in this press release is expressly qualified by this cautionary statement. Khiron disclaims any intention to update or revise any forward-looking information disclosed herein, whether as a result of new information, future events or otherwise, except as required by law.
NEITHER THE TSX VENTURE EXCHANGE, NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VEMTIRE EXCHANGE), ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS PRESS RELEASE.
View original content to download multimedia:https://www.prnewswire.com/news-releases/khiron-life-sciences-awarded-best-latin-american-cannabis-company-at-benzinga-cannabis-capital-conference-301623370.html
SOURCE Khiron Life Sciences Corp.
FAQ
What award did Khiron Life Sciences receive on September 13, 2022?
How many bottles has Khiron sold in Latin America since 2020?
What is the annual consultation capacity of Khiron's clinics in Colombia?
Where is Khiron Life Sciences expanding its operations?
